Literature DB >> 10328247

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

S Fahn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10328247     DOI： 10.1001/archneur.56.5.529

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  53 in total

1.  The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.

Authors:  Orazio Schillaci; Mariangela Pierantozzi; Luca Filippi; Carlo Manni; Livia Brusa; Roberta Danieli; Giorgio Bernardi; Giovanni Simonetti; Paolo Stanzione
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-08       Impact factor: 9.236

Review 2.  Neuroimaging trials of Parkinson's disease progression.

Authors:  John Seibyl; Danna Jennings; Rowena Tabamo; Ken Marek
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

Review 3.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

4.  Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Authors:  Nicholas H G Holford; Phylinda L S Chan; John G Nutt; Karl Kieburtz; Ira Shoulson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-20       Impact factor: 2.745

5.  Disease progression, drug action and Parkinson's disease: why time cannot be ignored.

Authors:  Nick Holford; John G Nutt
Journal:  Eur J Clin Pharmacol       Date:  2007-12-19       Impact factor: 2.953

Review 6.  Disease modification in Parkinson's disease.

Authors:  Claire Henchcliffe; W Lawrence Severt
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 7.  Limb use and complex ultrasonic vocalization in a rat model of Parkinson's disease: deficit-targeted training.

Authors:  Michelle R Ciucci; Sean T Ma; Jacqueline R Kane; Allison M Ahrens; Timothy Schallert
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

8.  Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Authors:  Michael J Marino; David L Williams; Julie A O'Brien; Ornella Valenti; Terrence P McDonald; Michelle K Clements; Ruiping Wang; Anthony G DiLella; J Fred Hess; Gene G Kinney; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

Review 9.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 10.  Utility of tolcapone in fluctuating Parkinson's disease.

Authors:  Fabrizio Stocchi; Maria Francesca De Pandis
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.